Login
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
South America
Harvard
Social Media
Formula 1
Artificial Intelligence
Premier League
Natural Disasters
Donald Trump
Soccer
Education
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Prothena to Evaluate Options After Phase 3 Birtamimab Failure; Shares Plunge

Summary by Seeking Alpha
Prothena halts birtamimab development after phase 3 failure in AL amyloidosis. Read more here.

2 Articles

All
Left
Center
Right
1
Seeking AlphaSeeking Alpha
Lean Right

Prothena to evaluate options after phase 3 birtamimab failure; shares plunge

Prothena halts birtamimab development after phase 3 failure in AL amyloidosis. Read more here.

·United States
Read Full Article
stocktitan.netstocktitan.net

Prothena Halts AL Amyloidosis Drug After Phase 3 Failure, Announces Major Workforce Cuts

Key trial missed mortality endpoint, forcing birtamimab discontinuation. Company plans substantial workforce reduction and cost cuts. See pipeline updates timeline.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Friday, May 23, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal